These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7633015)

  • 21. Nonlinear theophylline pharmacokinetics. A preventable cause of iatrogenic theophylline toxic reactions.
    Butts JD; Secrest B; Berger R
    Arch Intern Med; 1991 Oct; 151(10):2073-7. PubMed ID: 1929697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of clinafloxacin enantiomers in humans.
    Humphrey GH; Shapiro MA; Randinitis EJ; Guttendorf RJ; Brodfuehrer JI
    J Clin Pharmacol; 1999 Nov; 39(11):1143-50. PubMed ID: 10579144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.
    Kinzig-Schippers M; Fuhr U; Cesana M; Müller C; Staib AH; Rietbrock S; Sörgel F
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2359-64. PubMed ID: 9736563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective evaluation of elevated serum theophylline concentrations to determine if high concentrations are predictable.
    Greenberger PA; Cranberg JA; Ganz MA; Hubler GL
    Am J Med; 1991 Jul; 91(1):67-73. PubMed ID: 1858831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid.
    Staib AH; Harder S; Fuhr U; Wack C
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):289-3. PubMed ID: 2737798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.
    Wise R; Jones S; Das I; Andrews JM
    Antimicrob Agents Chemother; 1998 Feb; 42(2):428-30. PubMed ID: 9527799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone.
    Oh H; Nord CE; Barkholt L; Hedberg M; Edlund C
    Infection; 2000 Sep; 28(5):272-7. PubMed ID: 11073132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The effect of new quinolone antimicrobial agents and macrolide antibiotics on the clearance of theophylline].
    Honma M
    Nihon Rinsho; 1996 Nov; 54(11):3125-9. PubMed ID: 8950966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of a newly developed quinolone, T-3761, on pharmacokinetics of theophylline in rats.
    Hasegawa T; Nadai M; Haghgoo S; Yamaki K; Takagi K; Nabeshima T
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2138-40. PubMed ID: 8540732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of an ultralong sustained-release theophylline formulation when given twice daily in elderly patients with chronic obstructive pulmonary disease: monitoring implications.
    Armijo JA; Sánchez BM; Peralta FG; González-Ruiz M; Cuadrado A; Verdejo A; Cos MA; Arjona R
    Biopharm Drug Dispos; 2003 May; 24(4):165-71. PubMed ID: 12698500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic considerations in quinolone therapy.
    Nightingale CH
    Pharmacotherapy; 1993; 13(2 Pt 2):34S-38S. PubMed ID: 8474936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction between theophylline and enoxacin.
    Takagi K; Hasegawa T; Yamaki K; Suzuki R; Watanabe T; Satake T
    Int J Clin Pharmacol Ther Toxicol; 1988 Jun; 26(6):288-92. PubMed ID: 3165968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of enoxacin on theophylline pharmacokinetics].
    Liu YN
    Zhonghua Jie He He Hu Xi Za Zhi; 1992 Apr; 15(2):106-8, 128. PubMed ID: 1394590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of the pharmacokinetic profile of temafloxacin.
    Dudley MN
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():55-64. PubMed ID: 1664830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease.
    Bachmann K; Sullivan TJ; Reese JH; Jauregui L; Miller K; Scott M; Yeh KC; Stepanavage M; King JD; Schwartz J
    J Clin Pharmacol; 1995 May; 35(5):529-35. PubMed ID: 7657856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug monitoring: theophylline--comparison of 3 methods for determination].
    Kropp R; Göbel D
    Pneumologie; 1995 Feb; 49(2):60-4. PubMed ID: 7724504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease.
    Dal Negro R; Pomari C; Turco P
    Clin Pharmacokinet; 1993 Mar; 24(3):255-8. PubMed ID: 8462230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of lomefloxacin on theophylline pharmacokinetics.
    Nix DE; Norman A; Schentag JJ
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1006-8. PubMed ID: 2675751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.
    Randinitis EJ; Koup JR; Rausch G; Abel R; Bron NJ; Hounslow NJ; Vassos AB; Sedman AJ
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2536-42. PubMed ID: 11502526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A patient with theophylline-quinolone interaction. Not all quinolones are equal].
    Cárdenas Rodríguez M; Abad Sánchez A; Galán Macías C; Larios de la Carrera I
    Aten Primaria; 1996 Sep; 18(4):204-5. PubMed ID: 8963004
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.